Gilead Receives Favorable CHMP Opinion For HIV Prevention With Twice-Yearly Lenacapavir

Gilead Sciences, Inc. (NASDAQ:GILD) is among the 11 Best GLP-1 and Weight Loss Stocks to Invest in. Gilead Sciences, Inc. (NASDAQ:GILD) has received a favorable opinion from the European Medicines Agency’s CHMP for lenacapavir (Yeytuo®), a twice-yearly injectable HIV PrEP alternative. It will be the first of its kind in the EU if it is approved. Lenacapavir has been endorsed by the CHMP under the EU-M4all process to make it easier to obtain in low- and lower-middle-income nations. The final EC ruling is anticipated later this year.

The approval recommendation for lenacapavir is supported by solid Phase 3 data from the PURPOSE 1 and 2 studies. PURPOSE 1 exhibited 100% HIV prevention in 2,134 cisgender women from Sub-Saharan Africa, while PURPOSE 2 revealed 99.9% efficacy among 2,179 cisgender men and gender-diverse people. Lenacapavir had no adverse effects and performed better in both studies than once-daily oral Truvada. This long-acting PrEP could help with significant adherence and accessibility challenges, particularly for high-risk groups, as there were over 24,700 new HIV cases recorded in the EU in 2023.

While we acknowledge the risk and potential of GILD as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than GILD and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025.

Disclosure. None.